SEC Eyes Trading Around Inspire's Announcement Of Failed Diquafosol Study
This article was originally published in The Pink Sheet Daily
Executive Summary
A drop in the firm's stock on the morning that unsuccessful Phase III trial results for diquafosol tetrasodium were announced prompts a formal investigation by the Securities & Exchange Commission.
You may also be interested in...
Inspire Receives Second “Approvable” Letter For Diquafosol
Agency says trials failed to establish efficacy of the dry eye therapy.
Inspire Receives Second “Approvable” Letter For Diquafosol
Agency says trials failed to establish efficacy of the dry eye therapy.